Danaher Co. (NYSE:DHR – Get Free Report) announced a quarterly dividend on Tuesday, May 7th, RTT News reports. Stockholders of record on Friday, June 28th will be paid a dividend of 0.27 per share by the conglomerate on Friday, July 26th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 28th.
Danaher has raised its dividend payment by an average of 13.4% per year over the last three years. Danaher has a dividend payout ratio of 12.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Danaher to earn $8.71 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 12.4%.
Danaher Stock Down 0.1 %
Shares of NYSE DHR opened at $253.77 on Thursday. The firm’s 50-day moving average price is $255.07 and its 200-day moving average price is $246.14. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $187.96 billion, a price-to-earnings ratio of 43.01, a P/E/G ratio of 3.89 and a beta of 0.85. Danaher has a 12-month low of $182.09 and a 12-month high of $269.11.
Insiders Place Their Bets
In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 148,783 shares of company stock valued at $37,536,717. Insiders own 11.10% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on DHR. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday. Jefferies Financial Group began coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Citigroup upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $269.29.
Get Our Latest Research Report on DHR
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- How to invest in marijuana stocks in 7 stepsĀ
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- Manufacturing Stocks Investing
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- What are earnings reports?
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.